Adicet Bio Inc Stock Price, News & Analysis

Adicet Bio announced positive interim results for ADI-001, showing a 75% overall response rate and a 100% complete response rate in patients with relapsed/refractory Non-Hodgkin’s Lymphoma as of May 31, 2022. The Phase 1 study results indicate a favorable safety profile with no instances of dose-limiting toxicities or severe adverse events. Notably, 50% of evaluable patients with at least six months of follow-up remain cancer-free. The company aims to identify a recommended Phase 2 dose in late 2022 and plans to initiate pivotal studies in early 2023.

Adicet Bio, Inc. (Nasdaq: ACET) announced the granting of inducement awards on May 31, 2022, as part of its 2022 Inducement Plan to four employees hired in May 2022. The awards consist of non-qualified stock options for a total of 100,800 shares with an exercise price of $11.82 per share, the closing price on the grant date. The vesting schedule allows for one-fourth of the options to vest annually, with complete vesting occurring over four years, contingent on continued employment.

Adicet Bio, Inc. (ACET) announced positive preliminary results from its Phase 1 trial of ADI-001 for relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (NHL). As of February 14, 2022, the therapy showed a 67% complete response rate and a favorable safety profile, with no Grade ≥ 3 adverse events. Updated data will be presented at the ASCO Annual Meeting on June 6, 2022. Two patients maintained their complete response for over three months, despite one patient’s unrelated COVID-19 complications.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company, announced participation in two investor conferences in May and June 2022. The H.C. Wainwright Global Investment Conference will occur from May 23-26, with an on-demand presentation available from May 24 at 7:00 A.M. ET. The Jefferies Healthcare Conference runs from June 8-10, featuring a presentation by CEO Chen Schor on June 10 at 8:30 A.M. ET. Live webcasts will be accessible via Adicet’s Investors section on their website.

Adicet Bio, Inc. (Nasdaq: ACET) announced its financial results for Q1 2022, reporting a net income of $4.6 million, compared to a net loss of $21.3 million in the same period last year. The company maintains a strong cash position with $277.9 million as of March 31, 2022. Significant operational highlights include the acceptance of interim data from the ADI-001 Phase 1 trial for oral presentation at the ASCO Annual Meeting and the granting of Fast Track Designation by the FDA for ADI-001 targeting Non-Hodgkin’s lymphoma. R&D expenses rose to $13.5 million.

Adicet Bio, Inc. (Nasdaq: ACET) presented promising preclinical data for ADI-001 during the ISCT Annual Meeting. The study highlighted ADI-001's strong in vitro and in vivo tumor growth inhibition across various human lymphoma cell lines, showcasing its adaptive and innate anti-tumor mechanisms. Notably, the non-gene-edited ADI-001 CAR T cells exhibited enhanced resilience against host-mediated clearance compared to gene-edited alternatives. ADI-001 is currently undergoing a Phase 1 clinical trial aimed at treating relapsed or refractory B-cell Non-Hodgkin’s lymphoma.

Adicet Bio, Inc. (NASDAQ: ACET), a clinical-stage biotechnology company, announced the granting of inducement awards on April 29, 2022, to four newly hired employees. The awards include non-qualified stock options to purchase a total of 62,000 shares at an exercise price of $14.74 per share, equal to the stock's closing price on that date. The vesting schedule allows for one-fourth of the shares to vest after one year, with the remainder vesting in monthly installments over three years. These awards were granted under Adicet's 2022 Inducement Plan, adopted in January 2022.

Adicet Bio, Inc. (NASDAQ: ACET) announced updated safety and efficacy data from the Phase 1 study of ADI-001 for treating relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022. The oral presentation, titled 'A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta T cells in adults with B-cell malignancies', is scheduled for June 6, 2022, at 8:00 AM CDT, featuring Sattva Neelapu, MD, from MD Anderson Cancer Center.

Adicet Bio (Nasdaq: ACET) has announced that the FDA granted Fast Track Designation to its lead program ADI-001, targeting CD20 for treating relapsed or refractory B-cell Non-Hodgkin’s lymphoma. This investigational therapy is currently in a Phase 1 study assessing its safety and tolerability. The Fast Track status accelerates its development, addressing an unmet need in adult NHL. CEO Chen Schor expressed optimism about ADI-001’s unique approach and anticipates further data release from the trial in early 2022.